How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

18,217 results for

"grant funding" or "obtaining grants" or "getting grants" or "grant awards" or (grants and "how to")

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

17721. Omega-3 Fatty Acids for Treating Adults With Major Depression

information Responsible Party: Mark Rapaport, Professor, Emory University ClinicalTrials.gov Identifier: Other Study ID Numbers: DATR A5-ETMA ( Other Grant/Funding Number: National Institute of Mental Health ) First Posted: August 16, 2007 Last Update Posted: April 4, 2013 Last Verified: April 2013 Keywords provided by Mark Rapaport, Emory University: Major Depression Omega-3 Major Depressive Disorder Additional relevant MeSH terms: Layout table for MeSH terms Depression Depressive Disorder Depressive

2007 Clinical Trials

17722. Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF

ClinicalTrials.gov Identifier: Other Study ID Numbers: 0120050150 IRB # 0120050150 ( Other Grant/Funding Number: UMDNJ 106199 ) First Posted: July 23, 2007 Last Update Posted: November 11, 2015 Last Verified: November 2015 Keywords provided by Rutgers, The State University of New Jersey ( University of Medicine and Dentistry of New Jersey ): Acute decompensated heart failure Normal left ventricular ejection fraction Vasodilator therapy Additional relevant MeSH terms: Layout table for MeSH terms Heart Failure

2007 Clinical Trials

17723. A Multicenter Study of NAP (AL-108) in Schizophrenia

278200441003C ( Other Grant/Funding Number: NIMH ) First Posted: July 23, 2007 Results First Posted: January 27, 2017 Last Update Posted: March 10, 2017 Last Verified: January 2017 Keywords provided by University of California, Los Angeles: Cognition Schizophrenia Additional relevant MeSH terms: Layout table for MeSH terms Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders

2007 Clinical Trials

17724. Expanded Prenatal Testing Options and Informed Choice

interview: 5-item measure adapted from the Maternal Serum Screening Knowledge Questionnaire; risk comprehension was assessed by asking participants to estimate, out of 1000 pregnant women who had an amniocentesis, how many would experience a miscarriage caused by the procedure (women who reported the risk to be greater than zero but less than 10 were scored as correct), and out of 1000 pregnant women their age, how many are carrying a fetus affected by Down syndrome (we compared this risk (...) Development (NICHD) March of Dimes Investigators Layout table for investigator information Principal Investigator: Miriam Kuppermann, PhD, MPH University of California, San Francisco More Information Go to Additional Information: Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: University of California, San Francisco ClinicalTrials.gov Identifier: Other Study ID Numbers: 12-FY09-213 ( Other Grant

2007 Clinical Trials

17725. Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD

Numbers: 20405 SPD485.420-Reimherr ( Other Grant/Funding Number: Shire Pharma ) First Posted: July 25, 2007 Results First Posted: January 16, 2015 Last Update Posted: January 16, 2015 Last Verified: January 2015 Keywords provided by frederick reimherr, University of Utah: Attention Deficit Hyperactivity Disorder ADHD Adult Methylphenidate Transdermal System Daytrana Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit

2007 Clinical Trials

17726. Treatment Study for Cognitive Deficits in Schizophrenia

Layout table for investigator information Principal Investigator: Robert W Buchanan, M.D. University of Maryland More Information Go to Publications: Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: Stephen R. Marder, Principal Investigator, University of California, Los Angeles ClinicalTrials.gov Identifier: Other Study ID Numbers: TURNS02 HHSN278200441003C ( Other Grant/Funding Number: NIMH (...) grant ) First Posted: July 20, 2007 Results First Posted: October 31, 2014 Last Update Posted: October 31, 2014 Last Verified: October 2014 Keywords provided by Stephen R. Marder, University of California, Los Angeles: Cognition Schizophrenia Additional relevant MeSH terms: Layout table for MeSH terms Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders

2007 Clinical Trials

17727. Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia

, United States, 94304-1290 Sponsors and Collaborators US Department of Veterans Affairs Stanford University Takeda Investigators Layout table for investigator information Principal Investigator: Jamie M. Zeitzer, PhD VA Palo Alto Health Care System More Information Go to Publications of Results: Layout table for additonal information Responsible Party: US Department of Veterans Affairs ClinicalTrials.gov Identifier: Other Study ID Numbers: B6010-R 06-038R ( Other Grant/Funding Number: VA ) First

2007 Clinical Trials

17728. Elder Surgery

Institute on Aging (NIA) Investigators Layout table for investigator information Principal Investigator: Jefrey H. Silverstein, MD Icahn School of Medicine at Mount Sinai More Information Go to Layout table for additonal information Responsible Party: Icahn School of Medicine at Mount Sinai ClinicalTrials.gov Identifier: Other Study ID Numbers: GCO 00-0100 AG018772 ( Other Grant/Funding Number: National Institute on Aging (NIA) ) First Posted: July 26, 2007 Last Update Posted: March 16, 2016 Last

2007 Clinical Trials

17729. Gene Polymorphisms and Symptoms in Lung Cancer Patients

CA109043 ( Other Grant/Funding Number: NCI ) First Posted: July 20, 2007 Last Update Posted: May 8, 2017 Last Verified: May 2017 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by M.D. Anderson Cancer Center: Lung Cancer Epidemiology Symptoms Gene Polymorphisms Questionnaire Survey Additional relevant MeSH terms: Layout table for MeSH terms Lung Neoplasms Respiratory Tract Neoplasms Thoracic (...) of lung cancer. Condition or disease Intervention/treatment Lung Cancer Behavioral: Questionnaire Detailed Description: If you agree to take part in this study, upon being admitted for treatment, you will be asked about your symptoms (how severe they are and to what degree they affect your day-to-day functioning). You will be asked to fill out a symptoms questionnaire each time you are at the clinic for your treatment and for your follow-up visits. The questionnaire will take about 5 to 10 minutes

2007 Clinical Trials

17730. Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin

, OR More Information Go to Layout table for additonal information Responsible Party: US Department of Veterans Affairs ClinicalTrials.gov Identifier: Obsolete Identifiers: NCT00570596 Other Study ID Numbers: C4697-R CDR0000546570 ( Other Grant/Funding Number: VA RR&D ) NCRAR-VA-1810 ( Other Grant/Funding Number: VA RR&D ) OHSU-3288 ( Other Grant/Funding Number: VA RR&D ) First Posted: May 24, 2007 Results First Posted: January 29, 2014 Last Update Posted: March 7, 2014 Last Verified: February 2014

2007 Clinical Trials

17731. Abraxane and Alimta in Advanced Solid Tumors

Responsible Party: University of California, Davis ClinicalTrials.gov Identifier: Other Study ID Numbers: UCDCC#185 224355 ( Other Grant/Funding Number: UC Davis ) ABX027 ( Other Grant/Funding Number: Celgene ) H3E-US-I017 ( Other Grant/Funding Number: Eli Lilly ) First Posted: May 7, 2007 Results First Posted: March 8, 2017 Last Update Posted: January 10, 2018 Last Verified: January 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated (...) nanoparticle formulation together with pemetrexed may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of paclitaxel albumin-stabilized nanoparticle formulation when given together with pemetrexed and to see how well they work in treating patients with advanced non-small cell lung cancer, breast cancer, or other solid tumors. Condition or disease Intervention/treatment Phase Breast Cancer Lung Cancer Unspecified Adult Solid Tumor, Protocol Specific Drug

2007 Clinical Trials

17732. Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

experience dose-limiting toxicity. Once the MTD is determined, between16 to 25 new patients will be added to the MTD cohort depending on how well the CAT-8015 is tolerated. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Enrollment : 50 participants Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 (...) , United States, 90211 Contact: Marie Fuerst, RN, MS 310-285-7269 Principal Investigator: Peter Rosen, MD United States, Indiana Indiana University Cancer Center Not yet recruiting Indianapolis, Indiana, United States, 46202 Contact: Mary Cangany, RN, CCRP 317-278-4694 Principal Investigator: Larry Cripe, MD United States, Maryland Warren Grant Megnuson Clinical Center - NCI Clinical Trials Referral Office Recruiting Bethesda, Maryland, United States, 20892 Contact: NCI Clinical Trials Referral Office

2007 Clinical Trials

17733. First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: Jin Soo Lee, National Cancer Center, Korea ClinicalTrials.gov Identifier: Other Study ID Numbers: NCCCTS-05-126 D7913L00054 ( Other Grant/Funding Number: AstraZeneca ) First Posted: April 4, 2007 Last Update Posted: October 25, 2010 Last Verified: March 2010 Keywords provided by National Cancer Center, Korea: Adenocarcinoma NSCLC gemcitabine Cisplatin Gefitinib Never

2007 Clinical Trials

17734. Iodine I 131 With or Without Thyroid-Stimulating Hormone in Treating Patients Who Have Undergone Surgery for Thyroid Cancer

Responsible Party: University College, London ClinicalTrials.gov Identifier: Other Study ID Numbers: CDR0000522490 CRUK-HILO-BRD/05/83 ( Other Grant/Funding Number: Cancer Research UK ) ISRCTN56078540 ( Registry Identifier: ISRCTN ) EU-20665 CTA-20363/0217/001/0001 ( Other Identifier: Regulatory Authority Number ) 2005-003687-37 ( EudraCT Number ) First Posted: December 22, 2006 Last Update Posted: October 16, 2018 Last Verified: October 2017 Keywords provided by University College, London: stage I (...) : This randomized phase III trial is studying two different doses of iodine I 131 to compare how well they work when given with or without thyroid-stimulating hormone in treating patients who have undergone surgery for thyroid cancer. Condition or disease Intervention/treatment Phase Head and Neck Cancer Biological: recombinant thyroid-stimulating hormone Radiation: Radiodine ablation without rhTSH Phase 3 Detailed Description: OBJECTIVES: Primary Compare the percentage of successful remnant ablation at 6-8

2006 Clinical Trials

17735. Impact of Umbilical Cord Cleansing With 4.0% Chlorhexidine on Neonatal Mortality

Responsible Party: Dr. Abdullah H. Baqui, Professor, Johns Hopkins Bloomberg School of Public Health ClinicalTrials.gov Identifier: Other Study ID Numbers: IRB00000146 GHSA00030001900 ( Other Grant/Funding Number: Save the Children 131 ) First Posted: February 13, 2007 Last Update Posted: August 10, 2011 Last Verified: July 2007 Keywords provided by Johns Hopkins Bloomberg School of Public Health: omphalitis neonates umbilical cord infection infant mortality neonate morbidity chlorhexidine Additional (...) cleansing of the cord demonstrated in the Nepal trial, a replication study of this regimen and further investigations of more simple regimens are necessary. The number of treatments necessary to reduce neonatal mortality has important programmatic implications for who can deliver the intervention, and how it is packaged. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 28797 participants Allocation: Randomized Intervention Model

2007 Clinical Trials

17736. Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer

Faivre-Finn, MD The Christie NHS Foundation Trust More Information Go to Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: Sally Falk, Prof Corinne Faivre-Finn, The Christie NHS Foundation Trust ClinicalTrials.gov Identifier: Other Study ID Numbers: CDR0000531709 CHNT-CONVERT ( Other Identifier: Christie Hospital NHS Foundation Trust ) CHNT-CTAAC-CONVERT-C17052/A815 ( Other Grant/Funding Number (...) in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which schedule of radiation therapy is more effective when given together with chemotherapy in treating small cell lung cancer. PURPOSE: This randomized phase III trial is studying two different schedules of radiation therapy to compare how well they work when given together with cisplatin and etoposide

2007 Clinical Trials

17737. O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy

: RATIONALE: Drugs used in chemotherapy, such as O(6)-benzylguanine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving O(6)-benzylguanine together with temozolomide works in treating patients with glioblastoma multiforme that did not respond to previous (...) , radiotherapy, immunotherapy, or investigational agents Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00436436 Locations Layout table for location information United States, Maryland Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral

2007 Clinical Trials

17738. Diabetes Genome Project: A Prospective Registry to Identify Genetic Variation Among Diabetic Patients

: January 10, 2013 Sponsor: Saint Luke's Health System Information provided by (Responsible Party): Steven P. Marso, Saint Luke's Health System Study Details Study Description Go to Brief Summary: Previous scientific research has found multiple genes that affect the risk for developing heart disease or complications during the treatment of heart disease. Less is currently known about how patients with heart disease may differ on the basis of other ailments they may have and how these other ailments may (...) affect their treatment and prognosis. For this reason, researchers at the Mid America Heart Institute are conducting this research to find out how genes affect heart disease and recovery following angioplasty. The study will include patients with diabetes in order to determine if their genes are different from patients without diabetes. A total of 1,607 patients were enrolled. There were 2 groups of patients selected for this study. The first group of patients included into the study will be those

2007 Clinical Trials

17739. Neurovascular Coupling in Eyes of Glaucoma Patients

Director: Selim Orgül, MD University Eye Clinic Basel More Information Go to Layout table for additonal information Responsible Party: University Hospital, Basel, Switzerland ClinicalTrials.gov Identifier: Other Study ID Numbers: 084-GUK-2006-002 Swiss National Foundation ( Other Grant/Funding Number: 3200B0-113685 ) First Posted: February 1, 2007 Last Update Posted: December 16, 2014 Last Verified: December 2014 Additional relevant MeSH terms: Layout table for MeSH terms Glaucoma Ocular Hypertension (...) Study Description Go to Brief Summary: We hypothesize that glaucoma patients demonstrate an impaired retinal vascular response to the flicker stimulus, and that this disturbance is predictive of the progression of glaucomatous damage. The response of a major temporal superior and inferior retinal artery and vein to a 60 seconds 12.5 Hz flicker light stimulation in 50 glaucoma patients, 50 ocular hypertensives and 50 controls (using the Retinal Vessel Analyzer) and to investigate how intraocular

2007 Clinical Trials

17740. AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer

Investigator: Andrew Zhu Massachusetts General Hospital More Information Go to Additional Information: Publications of Results: Layout table for additonal information Responsible Party: National Cancer Institute (NCI) ClinicalTrials.gov Identifier: Other Study ID Numbers: NCI-2009-00130 05-311 ( Other Identifier: DFHCC IRB ) N02CO12400 ( Other Grant/Funding Number: US NIH Grant/Contract Award Number ) CDR0000526405 ( Registry Identifier: PDQ (Physician Data Query) ) First Posted: January 29, 2007 Results (...) Posted : October 31, 2016 Last Update Posted : October 31, 2016 Sponsor: National Cancer Institute (NCI) Information provided by (Responsible Party): National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: This phase II trial is studying how well AZD2171 works in treating patients with locally advanced unresectable or metastatic liver cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow

2007 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>